GBT Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 4.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Global Blood Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Global Blood Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k$0$200kTotal Insider BuyingTotal Insider Selling

Global Blood Therapeutics Share Price & Price History

Current Price: $68.49
Price Change: +0.30 (1.20%)
As of 11/2/2022 01:00 AM ET

This chart shows the closing price history over time for GBT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Global Blood Therapeutics Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Global Blood Therapeutics (NASDAQ:GBT)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at GBT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1B-$500M$0$500M$1BTotal InflowsTotal Outflows
Global Blood Therapeutics logo
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Read More on Global Blood Therapeutics

Today's Range

Now: $68.49
Low: $68.49
High: $68.49

50 Day Range

MA: $68.47
Low: $68.07
High: $68.49

52 Week Range

Now: $68.49
Low: $21.65
High: $73.02

Volume

74 shs

Average Volume

2,065,836 shs

Market Capitalization

$4.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45